申请人:OLEMA PHARMACEUTICALS, INC.
公开号:US20130178445A1
公开(公告)日:2013-07-11
Benzopyran compounds with strong anti-estrogenic activity and essentially no estrogenic activity are provided, which are OP-1038, which is 3-(4-hydroxyphenyl)-4-methyl-2-(4-2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol, and OP-1074, which is (2S)-3-(4-hydroxyphenyl)-4-methyl-2-(4-2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol. OP-1074 is a pure anti-estrogen when tested in the agonist mode and a complete anti-estrogen when tested in the antagonist mode. These compounds are useful for the treatment or prevention of a variety of conditions that are modulated through the estrogen receptor in mammals including humans.
本发明提供了具有强烈抗雌激素活性和基本无雌激素活性的苯并吡喃化合物,分别为OP-1038和OP-1074。其中,OP-1038为3-(4-羟基苯基)-4-甲基-2-(4-2-[(3R)-3-甲基吡咯烷-1-基]乙氧基}苯基)-2H-香豆素-7-醇,OP-1074为(2S)-3-(4-羟基苯基)-4-甲基-2-(4-2-[(3R)-3-甲基吡咯烷-1-基]乙氧基}苯基)-2H-香豆素-7-醇。在激动剂模式下测试时,OP-1074是纯抗雌激素,而在拮抗剂模式下测试时则是完全抗雌激素。这些化合物可用于治疗或预防哺乳动物,包括人类中通过雌激素受体调节的各种疾病。